Neumora Therapeutics (NMRA) Cash from Investing Activities (2022 - 2026)

Neumora Therapeutics has reported Cash from Investing Activities for 5 years, with the latest figure at $71000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 99.84% year-over-year to $71000.0; the trailing twelve-month figure through Mar 2026 stood at $124.4 million (up 0.67% YoY), and the FY2025 full-year result was $168.5 million, up 338.84% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $71000.0, down from $42.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $157.0 million in Q3 2024, with the low at -$150.0 million in Q1 2024.
• Average Cash from Investing Activities over 5 years is $11.0 million, with a median of $22.5 million recorded in 2023.
• Peak annual rise in Cash from Investing Activities reached 559.2% in 2024, while the deepest fall reached 5424.85% in 2024.
• Tracing NMRA's Cash from Investing Activities over 5 years: stood at -$8.0 million in 2022, then soared by 270.32% to $13.7 million in 2023, then slumped by 822.37% to -$98.8 million in 2024, then soared by 143.16% to $42.6 million in 2025, then tumbled by 99.83% to $71000.0 in 2026.
• The last three Cash from Investing Activities figures came in at $71000.0 (Q1 2026), $42.6 million (Q4 2025), and $51.3 million (Q3 2025), per Business Quant data.

Peer Comparison